ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Dual-Physical-Field Nanocatalysis: Injectable Hydrogel Enables Piezo-Photothermal Synergy for Breast Cancer Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Piezocatalytic therapy (PCT) harnesses mechanical energy to generate tumor-lethal reactive oxygen species (ROS), but its efficacy is limited by rapid electron-hole recombination and poor intratumoral retention. To overcome these limitations, we engineered heterostructured BiOCl@CuO nanosheets embedded in an injectable, conductive, thermosensitive hydrogel composed of Pluronic F127 (F127) and reduced graphene oxide (rGO), with rGO specifically enhancing the hydrogel's mechanical strength and conductivity, for the combinational treatment of breast cancer. Under ultrasound (US) stimulation, BiOCl@CuO establishes a strong interfacial electric field that enhances charge separation and accelerates the generation of ROS. In addition, near-infrared (NIR) irradiation activates BiOCl@CuO to convert light into heat, elevating intratumoral temperature and further amplifying ROS-mediated cytotoxicity while enabling photothermal therapy (PTT). The integrated BiOCl@CuO/F127@rGO hydrogel exhibits rapid sol-gel transition at physiological temperature, robust tissue adhesion, and sustained local retention. In vitro, the synergistic therapy induced marked ROS bursts and achieved 60% breast cancer cell ablation at 50 µg/mL with less than 10% toxicity to normal cells. In vivo, orthotopic breast tumors treated with US+NIR showed 90% regression, reduced proliferation and angiogenesis, activation of apoptotic and immunogenic cell death pathways, and favorable biocompatibility. Critically, the regimen triggered robust local immune activation, increasing intratumoral CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.